Reports Q4 revenue $758.0M, consensus $760.35M. "Our business showed continued resilience in the fourth quarter with a sequential improvement in constant currency revenue growth and margin expansion," said Liam Kelly, CEO. "In the quarter, we maintained healthy margins, and advanced our capital allocation strategy with the completion of the acquisition of Standard Bariatrics. As we look into 2023, we remain committed to our corporate strategy for durable growth."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TFX:
- Teleflex Announces Quarterly Dividend
- Teleflex Reports Fourth Quarter and Full Year 2022 Financial Results
- Teleflex announces key milestones in the release of two new catheters
- Teleflex Expands Interventional Cardiology Portfolio with Two New FDA-Cleared Catheter Devices for Use in Complex Percutaneous Coronary Interventions (PCI)
- Teleflex to Present at the 44th Annual Raymond James Institutional Investors Conference
